Literature DB >> 21235541

Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A.

T Rauhavirta1, S-W Qiao, Z Jiang, E Myrsky, J Loponen, I R Korponay-Szabó, H Salovaara, J A Garcia-Horsman, J Venäläinen, P T Männistö, R Collighan, A Mongeot, M Griffin, M Mäki, K Kaukinen, K Lindfors.   

Abstract

In coeliac disease, the intake of dietary gluten induces small-bowel mucosal damage and the production of immunoglobulin (Ig)A class autoantibodies against transglutaminase 2 (TG2). We examined the effect of coeliac patient IgA on the apical-to-basal passage of gluten-derived gliadin peptides p31-43 and p57-68 in intestinal epithelial cells. We demonstrate that coeliac IgA enhances the passage of gliadin peptides, which could be abolished by inhibition of TG2 enzymatic activity. Moreover, we also found that both the apical and the basal cell culture media containing the immunogenic gliadin peptides were able to induce the proliferation of deamidation-dependent coeliac patient-derived T cells even in the absence of exogenous TG2. Our results suggest that coeliac patient IgA could play a role in the transepithelial passage of gliadin peptides, a process during which they might be deamidated.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21235541      PMCID: PMC3074225          DOI: 10.1111/j.1365-2249.2010.04317.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Anti-reticulin antibody in jejunal juice in coeliac disease.

Authors:  H Mawhinney; A H Love
Journal:  Clin Exp Immunol       Date:  1975-09       Impact factor: 4.330

2.  Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease.

Authors:  Luigi Maiuri; Carolina Ciacci; Ida Ricciardelli; Loredana Vacca; Valeria Raia; Salvatore Auricchio; Jean Picard; Mohamed Osman; Sonia Quaratino; Marco Londei
Journal:  Lancet       Date:  2003-07-05       Impact factor: 79.321

3.  Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion.

Authors:  Shuo-Wang Qiao; Elin Bergseng; Øyvind Molberg; Jiang Xia; Burkhard Fleckenstein; Chaitan Khosla; Ludvig M Sollid
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

4.  Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia.

Authors:  Jorunn Stamnaes; Siri Dorum; Burkhard Fleckenstein; Daniel Aeschlimann; Ludvig M Sollid
Journal:  Amino Acids       Date:  2010-03-19       Impact factor: 3.520

5.  A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease.

Authors:  Sophie Hüe; Jean-Jacques Mention; Renato C Monteiro; ShaoLing Zhang; Christophe Cellier; Jacques Schmitz; Virginie Verkarre; Nassima Fodil; Seiamak Bahram; Nadine Cerf-Bensussan; Sophie Caillat-Zucman
Journal:  Immunity       Date:  2004-09       Impact factor: 31.745

6.  Alterations of the intestinal transport and processing of gliadin peptides in celiac disease.

Authors:  Tamara Matysiak-Budnik; Celine Candalh; Christophe Dugave; Abdelkader Namane; Christophe Cellier; Nadine Cerf-Bensussan; Martine Heyman
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

7.  Coeliac disease: in vivo toxicity of the putative immunodominant epitope.

Authors:  J S Fraser; W Engel; H J Ellis; S J Moodie; E L Pollock; H Wieser; P J Ciclitira
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

8.  Role of transglutaminase 1 in stabilisation of intercellular junctions of the vascular endothelium.

Authors:  Werner Baumgartner; Nikola Golenhofen; Agnes Weth; Takashi Hiiragi; Rob Saint; Martin Griffin; Detlev Drenckhahn
Journal:  Histochem Cell Biol       Date:  2004-06-25       Impact factor: 4.304

9.  Structural basis for gluten intolerance in celiac sprue.

Authors:  Lu Shan; Øyvind Molberg; Isabelle Parrot; Felix Hausch; Ferda Filiz; Gary M Gray; Ludvig M Sollid; Chaitan Khosla
Journal:  Science       Date:  2002-09-27       Impact factor: 47.728

10.  The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase.

Authors:  H Arentz-Hansen; R Körner; O Molberg; H Quarsten; W Vader; Y M Kooy; K E Lundin; F Koning; P Roepstorff; L M Sollid; S N McAdam
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

View more
  18 in total

Review 1.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

Review 2.  Therapeutic approaches for celiac disease.

Authors:  Nicholas M Plugis; Chaitan Khosla
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-05-09       Impact factor: 3.043

3.  Selected Probiotic Lactobacilli Have the Capacity To Hydrolyze Gluten Peptides during Simulated Gastrointestinal Digestion.

Authors:  Ruggiero Francavilla; Maria De Angelis; Carlo Giuseppe Rizzello; Noemi Cavallo; Fabio Dal Bello; Marco Gobbetti
Journal:  Appl Environ Microbiol       Date:  2017-06-30       Impact factor: 4.792

4.  Abnormal apical-to-basal transport of dietary ovalbumin by secretory IgA stimulates a mucosal Th1 response.

Authors:  J Abed; C Lebreton; G Champier; A Cuvillier; M Cogné; B Meresse; C Dugave; M Garfa-Traoré; B Corthésy; N Cerf-Bensussan; M Heyman
Journal:  Mucosal Immunol       Date:  2013-07-10       Impact factor: 7.313

5.  Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study.

Authors:  Tiina Rauhavirta; Mikko Oittinen; Rami Kivistö; Pekka T Männistö; J Arturo Garcia-Horsman; Zhuo Wang; Martin Griffin; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  J Clin Immunol       Date:  2012-08-10       Impact factor: 8.317

6.  A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects.

Authors:  Zsófia Simon-Vecsei; Róbert Király; Péter Bagossi; Boglárka Tóth; Ingrid Dahlbom; Sergio Caja; Éva Csosz; Katri Lindfors; Daniele Sblattero; Éva Nemes; Markku Mäki; László Fésüs; Ilma R Korponay-Szabó
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-22       Impact factor: 11.205

Review 7.  Current and emerging therapies for coeliac disease.

Authors:  Laura Kivelä; Alberto Caminero; Daniel A Leffler; Maria Ines Pinto-Sanchez; Jason A Tye-Din; Katri Lindfors
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-20       Impact factor: 46.802

Review 8.  The adaptive immune response in celiac disease.

Authors:  Shuo-Wang Qiao; Rasmus Iversen; Melinda Ráki; Ludvig M Sollid
Journal:  Semin Immunopathol       Date:  2012-04-26       Impact factor: 9.623

9.  The intestinal B-cell response in celiac disease.

Authors:  Luka Mesin; Ludvig M Sollid; Roberto Di Niro
Journal:  Front Immunol       Date:  2012-10-04       Impact factor: 7.561

Review 10.  Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.

Authors:  Tiina Rauhavirta; Minna Hietikko; Teea Salmi; Katri Lindfors
Journal:  Clin Rev Allergy Immunol       Date:  2019-08       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.